Antiresorptives: Safety Concerns—Clinical Perspective
- 24 October 2017
- journal article
- research article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 45 (7) , 859-863
Abstract
Antiresorptive drugs, such as amino-bisphosphonates and denosumab (Dmab), have dominated osteoporosis therapies for over 20 years. Since osteoporosis is a chronic disease, antifracture therapy could continue for the rest of a patient’s life. Phase III clinical trials for antiresorptive drugs assessed relatively small patient populations for short durations and excluded up to 80% of patients who might seek osteoporosis therapy in clinical practice. Postmarketing reports based upon millions of patient-years and long-term (>5 years) clinical administration have associated some previously unknown, rare adverse events with antiresorptive use including osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFFs). In the osteoporosis patient population, who receive much lower doses of bisphosphonate (BP) or Dmab, the incidence of ONJ is estimated at 0.001% to 0.01%, which is only slightly higher than that seen in the general population. AFFs are insufficiency or fissure transverse fractures originating on the lateral cortex of the subtrochanteric or diaphyseal region of the femur becoming oblique as they progress medially when complete. Incidence rates of AFF range from 1.8/100,000 per year with a 2-year BP exposure to 113/100,000 per year with BP exposure from 8 to 9.9 years. Most recent pathogenic hypotheses of these rare events will be discussed.Keywords
This publication has 45 references indexed in Scilit:
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionThe Lancet Diabetes & Endocrinology, 2017
- Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitisJournal of Bone and Mineral Research, 2012
- Pathophysiology of atypical femoral fractures and osteonecrosis of the jawOsteoporosis International, 2011
- Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and featuresBone, 2011
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone MassThe Journal of Clinical Endocrinology & Metabolism, 2011
- Denosumab and bisphosphonates: Different mechanisms of action and effectsBone, 2011
- Perspective: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the JawJournal of Bone and Mineral Research, 2009
- Economic comparison of diagnostic approaches for evaluating osteoporosis in older womenOsteoporosis International, 2005
- Pharmacokinetics/Pharmacodynamics of BisphosphonatesClinical Pharmacokinetics, 2005
- Bisphosphonates: Mechanisms of ActionEndocrine Reviews, 1998